Ping An Insurance Group is set to list its healthcare division

By Catherine Sturman
Ping An Healthcare and Technology is set to become the first out of four affiliates to be listed upon receiving approval from the Hong Kong Stock Exchan...

Ping An Healthcare and Technology is set to become the first out of four affiliates to be listed upon receiving approval from the Hong Kong Stock Exchange, South China Morning Post has reported.

At present, the company has 20 million active users, but the move will further enable the division to further grow its service offering outside of China, with the aim to raise up to HK$7.8 billion.

Despite the company’s poor performance, with a loss of up to $119.7 million in 2016, but received a 240% rise in revenue at the end of 2017.

See also

The Hong Kong Stock Exchange has approved the move, where Softbank Group remains the company’s main shareholder at 7.41%. Ping An Insurance will remain the sole dominant shareholder of the healthcare unit following on from the IPO listing.

The company’s digital health platform, Ping An Good Doctor, has up to 20 million active monthly users, with services such as booking GP appointments, wellness services, and encompasses over 3,000 hospitals and 7,000 pharmacies under its umbrella.

Up to 40% of its IPO proceeds will therefore be allocated towards developing these services further, investing in new technologies and link towards its overall expansion strategy.

If successful, Ping An Insurance aim to spin off three other outlets under its remit, which will see it gain further presence on an international scale.

Share

Featured Articles

Grifols & Orange Business Launch Egypt Plasma Project

Grifols & Orange Business Complete landmark phase of Data Centre for Plasma Derivatives Facility, designed to boost healthcare in Egypt

Healthcare business roundup: Eli Lilly, Novo Nordisk, Aspen

Eli Lilly's experimental cardiovascular drug ‘promising’; Aspen Pharmacare to manufacture mpox vaccines; Novo Nordisk says Ozempic shortage ‘worsening’

Global Health Funding 'Facing Post-Pandemic Challenges'

IHME report highlights shifting priorities and economic pressures affecting global health financing, despite increase in funding since pre-COVID levels

The Merck Group: Pharma's History & Innovation in India

Medical Devices & Pharma

How CVS Health is Rising to the Omnichannel Challenge

Procurement & Supply Chain

Kinaxis: Pharma Seeing Euro-wide Supply Chain Challenges

Procurement & Supply Chain